| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3396950 | Clinical Microbiology and Infection | 2011 | 5 Pages |
Abstract
The relevant efficacy of monoclonal antibodies (mAbs) has resulted in the successful treatment of several diseases, although susceptibility to infections remains a major problem. This review summarizes aspects of the literature regarding viral infections and mAbs, specifically addressing the risk of infection/reactivation, the measures that can reduce this risk, and the role played by the laboratory of clinical virology in monitoring patients undergoing mAb therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
R. Cavallo,